Influenza Antivirals for Prevention and Treatment in Immunocompromised People
The Journal of Infectious Diseases · 17.10.2025 · 232 (Supplement_3) · S243-S253
DOI: 10.1093/infdis/jiaf217 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 17.10.2025. Verfasst von Madeleine R Heldman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Immunocompromised Host, Influenza, Human, Antiviral Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH.
Abstract (Originalsprache)
Antivirals form a foundation for protecting immunocompromised individuals (ICIs) from influenza complications. Neuraminidase inhibitors have demonstrated benefit for both prophylaxis and treatment in ICIs, including when given >48 hours after symptom onset. Baloxavir is a newer antiviral that has potent effects on viral kinetics in immunocompetent people, but data on baloxavir in ICIs are currently limited. Optimization of antiviral therapy to minimize viral replication within ICIs and reduce the risk of treatment-emergent antiviral resistance (eg, through combination regimens) may prevent viral evolution within ICIs and mitigate transmission of virulent or resistant variants to the general public. Unfortunately, ICIs have been excluded from most clinical trials evaluating novel influenza preventive and therapeutic strategies. Inclusion of ICIs in such clinical trials is essential to facilitate acquisition of clinical and virologic data in patients with specific immunocompromising conditions and ensure that ICIs have equitable access to valuable interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA.
ORCID-Profile: Madeleine R Heldman, Michael J Boeckh, Michael G Ison
Förderung
- NIH
Zitieren
APA
Heldman, M. R., Boeckh, M. J., & Ison, M. G. (2025). Influenza Antivirals for Prevention and Treatment in Immunocompromised People. The Journal of Infectious Diseases, 232(Supplement_3), S243-S253. https://doi.org/10.1093/infdis/jiaf217
Vancouver
Heldman MR, Boeckh MJ, Ison MG. Influenza Antivirals for Prevention and Treatment in Immunocompromised People. The Journal of Infectious Diseases. 2025;232(Supplement_3):S243-S253. doi:10.1093/infdis/jiaf217
BibTeX
@article{Heldman2025,
author = {Heldman, Madeleine R and Boeckh, Michael J and Ison, Michael G},
title = {Influenza Antivirals for Prevention and Treatment in Immunocompromised People},
journal = {The Journal of Infectious Diseases},
year = {2025},
volume = {232},
number = {Supplement_3},
pages = {S243--S253},
doi = {10.1093/infdis/jiaf217}
}
EUVIMED